Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

NCT02916706 Phase 3 COMPLETED Results posted

This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).

Details

Lead sponsor	Tanabe Pharma Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	254
Start date	2016-09

Conditions

• Type 2 Diabetes Mellitus

Interventions

• Teneligliptin 20mg
• Placebo

Primary outcomes

• Change in HbA1c From Baseline to Week 24 — at Day 1(baseline) and Week 24
  The change in HbA1c from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.

Countries

China